Natsumi Yamamura-Miyazaki1, Toshimi Michigami2,3, Keiichi Ozono4, Katsusuke Yamamoto2, Yukiko Hasuike5. 1. Department of Pediatric Nephrology and Metabolism, Osaka Women's and Children's Hospital, 840 Murodo-cho, Izumi, Osaka, 594-1101, Japan. yamamur@wch.opho.jp. 2. Department of Pediatric Nephrology and Metabolism, Osaka Women's and Children's Hospital, 840 Murodo-cho, Izumi, Osaka, 594-1101, Japan. 3. Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, 840 Murodo-cho, Izumi, Osaka, 594-1101, Japan. 4. Department of Pediatrics, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. 5. Department of Cardiovascular and Renal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Abstract
BACKGROUND: Fibroblast growth factor 23 (FGF23) levels increase as kidney function decreases and are associated with increased mortality in patients with chronic kidney disease (CKD). Inflammation has also been shown to increase FGF23 production in adults; however, this has not been validated in pediatric patients with CKD. Furthermore, previous studies on children involved a single measurement of FGF23 without a follow-up, and a few studies have examined changes in FGF23 levels. METHODS: We measured the levels of serum intact FGF23, tumor necrosis factor-α (TNF-α), and interleukin-6 as parameters of inflammation and other variables related to bone metabolism at baseline and after 1 year in 62 pediatric patients with CKD (stages 2-5D, 1-16 years old). Factors related to changes in FGF23 levels were investigated. RESULTS: The median age of patients at the evaluation was 10.5 years (interquartile range 6.0-14.0), and the estimated glomerular filtration rate (eGFR) was 59.0 mL/min/1.73 m2 (45.1-69.3). Primary diseases included congenital anomalies of the kidney and urinary tract, ischemic kidney, and glomerulonephritis. The baseline value of FGF23 was 66.5 pg/mL (48.3-96.4), and percent change in FGF23 levels after 1 year was 8.5% (- 29.9-74.7). The percent change in FGF23 levels showed a negative correlation with that in eGFR (P = 0.010), and a positive correlation with that in TNF-α levels (P = 0.035). A multivariate linear regression analysis identified TNF-α as an independent factor increasing FGF23 levels. CONCLUSIONS: An increase in TNF-α levels is associated with elevation of FGF23 levels in pediatric patients with CKD.
BACKGROUND: Fibroblast growth factor 23 (FGF23) levels increase as kidney function decreases and are associated with increased mortality in patients with chronic kidney disease (CKD). Inflammation has also been shown to increase FGF23 production in adults; however, this has not been validated in pediatric patients with CKD. Furthermore, previous studies on children involved a single measurement of FGF23 without a follow-up, and a few studies have examined changes in FGF23 levels. METHODS: We measured the levels of serum intact FGF23, tumor necrosis factor-α (TNF-α), and interleukin-6 as parameters of inflammation and other variables related to bone metabolism at baseline and after 1 year in 62 pediatric patients with CKD (stages 2-5D, 1-16 years old). Factors related to changes in FGF23 levels were investigated. RESULTS: The median age of patients at the evaluation was 10.5 years (interquartile range 6.0-14.0), and the estimated glomerular filtration rate (eGFR) was 59.0 mL/min/1.73 m2 (45.1-69.3). Primary diseases included congenital anomalies of the kidney and urinary tract, ischemic kidney, and glomerulonephritis. The baseline value of FGF23 was 66.5 pg/mL (48.3-96.4), and percent change in FGF23 levels after 1 year was 8.5% (- 29.9-74.7). The percent change in FGF23 levels showed a negative correlation with that in eGFR (P = 0.010), and a positive correlation with that in TNF-α levels (P = 0.035). A multivariate linear regression analysis identified TNF-α as an independent factor increasing FGF23 levels. CONCLUSIONS: An increase in TNF-α levels is associated with elevation of FGF23 levels in pediatric patients with CKD.
Authors: Jocelyn S Garland; Rachel M Holden; Robert Ross; Michael A Adams; Robert L Nolan; Wilma M Hopman; A Ross Morton Journal: J Diabetes Complications Date: 2013-10-11 Impact factor: 2.852
Authors: Jair Munoz Mendoza; Tamara Isakova; Xuan Cai; Liz Y Bayes; Christian Faul; Julia J Scialla; James P Lash; Jing Chen; Jiang He; Sankar Navaneethan; Lavinia Negrea; Sylvia E Rosas; Matthias Kretzler; Lisa Nessel; Dawei Xie; Amanda Hyre Anderson; Dominic S Raj; Myles Wolf Journal: Kidney Int Date: 2016-12-22 Impact factor: 10.612
Authors: Daniela Egli-Spichtig; Pedro Henrique Imenez Silva; Bob Glaudemans; Nicole Gehring; Carla Bettoni; Martin Y H Zhang; Eva M Pastor-Arroyo; Désirée Schönenberger; Michal Rajski; David Hoogewijs; Felix Knauf; Benjamin Misselwitz; Isabelle Frey-Wagner; Gerhard Rogler; Daniel Ackermann; Belen Ponte; Menno Pruijm; Alexander Leichtle; Georg-Martin Fiedler; Murielle Bochud; Virginia Ballotta; Sandra Hofmann; Farzana Perwad; Michael Föller; Florian Lang; Roland H Wenger; Ian Frew; Carsten A Wagner Journal: Kidney Int Date: 2019-05-14 Impact factor: 10.612
Authors: Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf Journal: Kidney Int Date: 2011-03-09 Impact factor: 10.612
Authors: Anthony A Portale; Myles S Wolf; Shari Messinger; Farzana Perwad; Harald Jüppner; Bradley A Warady; Susan L Furth; Isidro B Salusky Journal: Clin J Am Soc Nephrol Date: 2016-08-25 Impact factor: 8.237
Authors: Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245